EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

Antoine Adenis iD, François Ghiringhelli, Ludovic Gauthier, Thibault Mazard iD, Ludovic Evesque, Alexandre Evrard, Patrick Chalbos, Aurore Moussion iD, Sophie Gourgou iD, Marc Ychou iD

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04682-4 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Antoine Adenis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Montpellier Cancer Institute (ICM), INSERM U1194, Montpellier University, Montpellier, 34298, France. antoine.adenis@icm…. Hauptthemen laut MEDLINE: Pyridines, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer Healthcare Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The combination of bevacizumab and FOLFIRINOX is used in patients with RAS-mutant metastatic colorectal cancer (RASm-mCRC). Regorafenib, an oral multi-tyrosine kinase inhibitor, has antiangiogenic properties, cytostatic effects and also true cytotoxic effects, unlike bevacizumab. The aim of this study was to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of the regorafenib-FOLFIRINOX combination in patients with RASm-mCRC.

Methods

The FOLFIRINOX-R trial was a phase 1/2 study where the dose-escalation part (3 + 3 design with three dose levels, DLs) was completed before its early termination. FOLFIRINOX (14-day cycle) included oxaliplatin (standard dose), folinic acid, fluorouracil and irinotecan (150 or 180 mg/m²). Regorafenib (120 or 160 mg daily) was given from day 4 to day 10 of each cycle. Dose-limiting toxicity (DLT) was studied in the first three cycles. Eligibility criteria included ECOG performance status ≤ 1 and not previously treated RASm-mCRC.

Results

Thirteen patients (median age: 65 years; min-max: 40–76) were enrolled. DLT could not be evaluated in one patient (DL3) due to poor observance. The median treatment duration and median follow-up were 6.2 (min-max: 2.3–10) and 13.4 (min-max: 3.8–18.0) months, respectively. Dose was modified in 12/13 (92%) patients. One grade 3 hypokalemia occurred at DL2. MTD was not reached at DL3. Grade 3 diarrhea was recorded in 7/13 patients (13 events) equally distributed in all DLs.

Conclusion

The RP2D for this regorafenib-FFX combination could not be determined due to a high prevalence of grade 3 diarrhea related to treatment as advised by our Independent Data Monitoring Committee. Trial registration numbers ClinicalTrials.gov : NCT03828799.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsPhenylurea CompoundsIrinotecanFluorouracilLeucovorinOxaliplatinMaximum Tolerated DoseHumansFemaleMaleMiddle AgedAgedAdultMutationDose-Response Relationship, DrugNeoplasm Metastasis

Stichwörter der Autor:innen

Colorectal cancerFOLFIRINOXPhase 1 trialRecommended phase 2 doseRegorafenib

Substanzen

regorafenibPyridinesPhenylurea CompoundsIrinotecanFluorouracilLeucovorinOxaliplatinfolfirinox

Autor:innen und Institutionen

  • Medical Oncology Department, Montpellier Cancer Institute (ICM), INSERM U1194, Montpellier University, Montpellier, 34298, France. antoine.adenis@icm.unicancer.fr.
  • Medical Oncology Department, Centre Georges-Francois Leclerc, Dijon, France.
  • Biometrics Unit, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France.
  • Medical Oncology Department, Montpellier Cancer Institute (ICM), INSERM U1194, Montpellier University, Montpellier, 34298, France.
  • Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.
  • Montpellier Cancer Research Institute (IRCM), INSERM U1194, Montpellier University, Montpellier, France.

ORCID-Profile: Antoine Adenis, Thibault Mazard, Aurore Moussion, Sophie Gourgou, Marc Ychou

Förderung

  • Bayer Healthcare Pharmaceuticals

Zitieren

APA

Adenis, A., Ghiringhelli, F., Gauthier, L., Mazard, T., Evesque, L., Evrard, A., Chalbos, P., Moussion, A., Gourgou, S., & Ychou, M. (2024). Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04682-4

Vancouver

Adenis A, Ghiringhelli F, Gauthier L, Mazard T, Evesque L, Evrard A, et al. Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04682-4

BibTeX
@article{Adenis2024,
  author = {Adenis, Antoine and Ghiringhelli, François and Gauthier, Ludovic and Mazard, Thibault and Evesque, Ludovic and Evrard, Alexandre and Chalbos, Patrick and Moussion, Aurore and Gourgou, Sophie and Ychou, Marc},
  title = {Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04682-4}
}
Kostenlos starten →